Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Bofanglutide

GZR18-BWM-303

Gan & Lee Pharmaceuticals · Phase 3 · Recruiting · Enrollment 500

NCT07292441

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Placebon/rn/rn/rn/r
GZR18 injection Dose1n/rn/rn/rn/r
GZR18 injection Dose2n/rn/rn/rn/r
GZR18 injection Dose3n/rn/rn/rn/r

Not shown

  • Placebo: endpoint not reported
  • GZR18 injection Dose1: endpoint not reported
  • GZR18 injection Dose2: endpoint not reported
  • GZR18 injection Dose3: endpoint not reported